Analysis of occurrence frequency of genotypes of VEGF (vascular endothelial growth factor) in two polymorphic gene regulatory region positions in combination with other genotypes of those angiogenic cytokines and metalloproteinases in groups of healthy people of different ages has been carried out. The SNP promoter of genes TNFА -863 C ? A, TNFА -308 G ? A, TNFА -238 G ? A, IL1? -511 T ? С, IL1? -31 С ? T, IL-4 -590 С ? T, IL-6 -174 G ? C, IL-10 -1082 G ? A and IL-10 -592 А ? С, genes of matrix metalloproteinases MMP2-1306 C ? T, MMP9 -1562 C ? T, and gene of VEGF-vascular endothelial growth factor VEGF -2578 А ? С and VEGF +936 C ? T have been investigated. The statistical analysis of the studies results included such indicators as the rate of occurrence of genes, genotypes and their combinations, specificity, odds ratio (or) with 95% confidence intervals (CI). The group surveyed ranked 219 people; the investigated signs were compared in the subgroup of young people (less than 35 years - 103) and senior citizens (55 years and over - 116 persons). It has been found that among older people the whole range of combined genetic traits, including VEGF and homozygous genotypes of polymorphic variants of genes of cytokines is fully absent, with the high frequency in the group of young people. The frequency of other genetic combinations, which are more frequent among young people, significantly reduced (by several times). This group combined genetic traits, which frequency decreases with age, most often detected in AC and CC options polymorphic gene VEGF-2578 positions and
VEGF +936, associated with high levels of production growth factor of vascular endothelial function. It can be assumed that the presence of such combinations of genotypes in the young man's genome is an adverse prognostic sign, pointing to the short lifespan of a given individual that probably gives an indication of the low level of health state and his inclusion in the group of high risk diseases.
1. Konenkov V.I., Borodin Y.I., Lyubarsky M.S. Lymphology. Novosibirsk: Manuscript, 2012.1001 p.(in Russian)
2. Konenkov V.I., Pokushalov E.A., Poveschenko O.V. Characteristic of a phenotype mobilized by COE-factor of cells of peripheral blood at patients with chronic cardiac insufficiency // Kletochnye tekhnologii v biologii i meditsine. 2012. (1). 9-14. (in Russian)
3. Konenkov V.I., Shevchenko А.В., Prokofev V.F., Voevoda M.I. Polymorphism of genes of fibers - regulators of an inflammation, at an atherosclerosis, the complicated development of a sharp heart attack of a myocardium // Ateroskleroz. 2011.7. (1) .5-18. (in Russian)
4. Poveshchenko A.F., Konenkov V.I. Mechanisms and factors of angiogenesis // Uspekhi fiziologicheskikh nauk. 2010. 41. (2). 68-89. (in Russian)
5. Poveshchenko O., Poveshchenko A., Konenkov V.I. Phisiologic and cytologic bases of cellular regulation of angiogenesis // Uspekhi fiziologicheskikh nauk. 2012. 43. (3). 48-61. (in Russian)
6. Filchenkov A.A. Lymphangiogenesis and metastatic of tumours // Onkologiya. 2009.11.(2).94-102. (in Russian)
7. Shevchenko A.V., Golovanova O.V.,Konenkov V,I. Features of the IL-1, IL-4, IL-5, IL-6, IL-10 and TNF-? cytokine genes promoter polymorphism of Western Siberia Caucasoid population // Immunologiya. 2010. (4). 176-181. (in Russian).
8. Shevchenko A.V., Golovanova O.V.,Konenkov V,I. et al. Analysis of the gene polymorphism of matrix metalloproteinase-2 and -9 in patients with coronary heart disease // Terapevticheskiy arkhiv. 2010. 82. (1). 31-34. (in Russian)
9. Shevchenko A.V., Konenkov V.I., Golovanova O.V. et al. The polymorphism VEGFA (С-2578A, C+936T) genes in patients with breast cancer // Meditsinskaya immunologiya. 2012. 14. (1-2). 87-94. (in Russian)
10. Ackerman H., Usen S., Mott R. Haplotypic analysis of the TNF locus by association efficiency and entropy // Genome Biol. 2003. 4. 24-27.
11. Amin A.H., Abd Elmageed Z.Y., Nair D. et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice // Lab. Invest. 2010. 90. (7). 985-996.
12. Barcelos L.S., Duplaa C., Krдnkel N. et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling // Circ. Res. 2009. 104. (9). 1095-1102.
13. Beekman M., Blanche H., Perola M. et al. GENA consortium. Genome-wide linkage analysis for human longevity: Genetics of Healthy Aging Study // Aging Cell. 2013. 12. (2). 184-193.
14. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing // J. R. Stat. Soc. Series B. Stat. Methodol. 1995. 57. 289-300.
15. Capri M., Salvioli S., Sevini F. et al. Understanding and modulating aging // Ann. N. Y. Acad. Sci. 2006. 5. (1067). 252-263.
16. De Haro J., Acin F., Lopez-Quintana A. et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease // Heart Vessels. 2009. 24. (5). 321-328.
17. Del Bo R., Ghezzi S., Scarlato M. et al. Role of VEGF gene variability in longevity: a lesson from the Italian population // Neurobiol. Aging. 2008. 29. (12). 1917-1922.
18. Dvorac H.F. Vascular permeability factor // J. Clin. Oncol. 2002. 280. 6. 1358-1366.
19. Eremina V., Jefferson J.A., Kowalewska J. et al. VEGF inhibition and renal thrombotic microangiopathy // N. Engl. J. Med. 2008. 358. (11). 1129-1136.
20. Goligorsky M.S., Kuo M.C., Patschan D., Verhaar M.C. Review article: endothelial progenitor cells in renal disease // Nephrology (Carlton). 2009. 14. (3). 291-297.
21. Gupta R., Tongers J., Losordo D.W. Human studies of angiogenic gene therapy // Circ. Res. 2009. 105. (8). 724-736.
22. Hsie Y., Chang C., Tsai F. T allele for VEGF gene polymorphism at 5-untranslated region is associated with higher susceptibility of leiomyoma // Biochem. Genet. 2008. 46. (5-6). 356-361.
23. Izzedine H., Massard C., Spano J.P. et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management // Eur. J. Cancer. 2010. 46. (2). 439-448.
24. Jaumdally R.J., Goon P.K., Varma C. et al. Effects of atorvastatin on circulating CD34+/CD133+/CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus // J. Intern. Med. 2010. 267. (4). 385-393.
25. Kawamura A., Horie T., Tsuda I. et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs // J. Artif. Organs. 2006. 9. (4). 226-233.
26. Kimoto K., Kubota T. Anti-VEGF agents for ocular angiogenesis and vascular permeability // J. Ophthalmol. 2012. 2012. 852183.
27. Kohno R., Hata Y., Mochizuki Y. et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab // Br. J. Ophthalmol. 2010. 94. (9). 1215-1218.
28. Li Calzi S., Neu M.B., Shaw L.C., Grant M.B. Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetes-associated deficits // EPMA J. 2010. (1). 88-100.
29. Moazzami K., Majdzadeh R., Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia // Cochrane Database Syst. Rev. 2011. 12. CD008347.
30. Nasu T., Maeshima Y., Kinomura M. et al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy // Diabetes. 2009. 58. (10). 2365-2375.
31. Poveshchenko O.V., Poveshchenko A.F., Konenkov V.I. Endothelial progenitor cells and neovasculogenesis // Biol. Bull. Rev. 2012. 2. (4). 333-339.
32. Reinhard H., Jacobsen P.K., Lajer M. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes // Diabetologia. 2010. 53. (10). 2129-2133.
33. Renner W., Kotschan S., Hoffman C. et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma level // J. Vasc. Rev. 2000. 37. 443-448.
34. Ruiz-Salmeron R., de la Cuesta-Diaz A., Constantino-Bermejo M. et al. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia // Cell. Transplant. 2011. 20. (10). 1629-1639.
35. Schatteman G.C., Dunnwald M., Jiao C. Biology of bone marrow-derived endothelial cell precursors // Am. J. Physiol. Heart Circ. Physiol. 2007. 292. (1). 1-18.
36. Schlager O., Giurgea A., Schuhfried O. et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial // Atherosclerosis. 2011. 217. (1). 240-248.
37. Shahbazi M., Fryer A.A., Pravika V. et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection // J. Am. Soc. Nephrol. 2002. 13. 260-264.
38. Takahashi M., Yoshimoto T., Kubo H. Molecular mechanism of lymphoangiogenesis // Int. J. Hemat. 2004. 80. (1). 29-34
39. Wei L., Liu Y., Chen G. Differentiation of lymphatic endothelial cells from bone marrow mesenchymal stem cells with VEGF // Lymphology. 2012. 45. 177-187.
